ANTITHROMBOTIC properties of aspirin were first proposed 25 years ago when aspirin was shown to inhibit platelet aggregation and to prolong bleeding time,1-5 but it is only in the past 10 years that the therapeutic benefit of aspirin's antithrombotic properties has been conclusively established by randomized controlled trials.6-14 Early studies used relatively large aspirin doses of approximately 1000 mg, but with increased understanding of the mechanism of its antithrombotic effect, lower-dose regimens were evaluated and were shown to be as effective with less gastrointestinal side effects.7,15,16 Antithrombotic benefit from aspirin has been demonstrated with as little as 75 mg/d for unstable angina,8 160 mg/d for acute myocardial infarction,17 100 mg/d for aortocoronary grafts,18,19 and probably as little as 30 mg/d for minor cerebral ischemic events.16
The trend to use low doses of aspirin increases compliance and reduces gastrointestinal side effects but has the potential
Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more
Subscribe for full-text access to content from 1998 forward and a host of useful features
Activate your current subscription (AMA members and current subscribers)
Purchase Online Access to this article for 24 hours
Thank you for submitting a comment on this article. It will be reviewed by JAMA Internal Medicine editors. You will be notified when your comment has been published. Comments should not exceed 500 words of text and 10 references.
Do not submit personal medical questions or information that could identify a specific patient, questions about a particular case, or general inquiries to an author. Only content that has not been published, posted, or submitted elsewhere should be submitted. By submitting this Comment, you and any coauthors transfer copyright to the journal if your Comment is posted.
* = Required Field
Disclosure of Any Conflicts of Interest*
Indicate all relevant conflicts of interest of each author below, including all relevant financial interests, activities, and relationships within the past 3 years including, but not limited to, employment, affiliation, grants or funding, consultancies, honoraria or payment, speakers’ bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued. If all authors have none, check "No potential conflicts or relevant financial interests" in the box below. Please also indicate any funding received in support of this work. The information will be posted with your response.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 10
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
and access these and other features:
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.